Buscar
HUTCHMED (China) Ltd
HCMAñadir a la lista de seguimiento
11.130USD
+0.360+3.34%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.97BCap. mercado
20.58P/E TTM
Más Datos de HUTCHMED (China) Ltd Compañía
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Información de HUTCHMED (China) Ltd
Símbolo de cotizaciónHCM
Nombre de la empresaHUTCHMED (China) Ltd
Fecha de salida a bolsaMay 19, 2006
Director ejecutivoCheng (Chig Fung)
Número de empleados1811
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 19
Dirección48th Floor, Cheung Kong Center, 2 Queen's Road Central
Ciudad
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísHong Kong
Código postal- -
Teléfono85221281188
Sitio Webhttps://www.hutch-med.com/
Símbolo de cotizaciónHCM
Fecha de salida a bolsaMay 19, 2006
Director ejecutivoCheng (Chig Fung)
Ejecutivos de HUTCHMED (China) Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Mr. Charles George Rupert Nixon
Mr. Charles George Rupert Nixon
Group General Counsel
Group General Counsel
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de HUTCHMED (China) Ltd?
Los cinco principales accionistas de HUTCHMED (China) Ltd son: Dr. Renu Bhatia
¿Cuántas instituciones poseen acciones de HUTCHMED (China) Ltd (HCM)?
A fecha de 2026Q1, 139 instituciones poseen acciones de HUTCHMED (China) Ltd, con un valor de mercado combinado de aproximadamente 5.33M, lo que representa el 3.05% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -5943889.00.